Where is PACE located?

PACE is headquartered in Cheshire, United Kingdom.

Where does PACE rank among its competitors?

PACE ranks 173rd amongst 221 active competitors, of which 78 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was smartbax, which secured $7.19M in Jun, 2026.

Who are the top competitors of PACE?

PACE's top competitors include Spero Therapeutics, LimmaTech Biologics and Bioversys. Among them, smartbax secured the most recent funding round in June, 2026.

PACE - 2026 Company Profile & Competitors

Company Details

Developer of antimicrobial drugs and diagnostics. The company is pioneering the development of tests and treatments to tackle antimicrobial resistance.

Key Metrics

Founded Year

2023

Location

Cheshire, United Kingdom

Stage

Unfunded

Ranked

173^rd among 221 active competitors

Investment & Acquisitions

InnotiveDx & 3 more

Similar Companies

Spero Therapeutics & 273 more

View PACE's full profile

PACE has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PACE include Spero Therapeutics, LimmaTech Biologics and Bioversys. Here is the list of Top 10 competitors of PACE, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	67/100
2nd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	64/100
3rd	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	63/100
4th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	60/100
5th	smartbax 2021, Munich (Germany), Seed	Developer of multi-targeted antibacterial compounds	$7.51M	Anobis Asset, Bayern Kapital & 4 others	60/100
6th	Pattern Bioscience 2016, Austin (United States), Series C	Provider of multiple diagnostics platforms for infectious diseases	$105M	Illumina Ventures, CARB-X & 3 others	59/100
7th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Hillhouse & 12 others	58/100
8th	Clarametyx 2019, Columbus (United States), Series A	Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections	$33M	Ohio Innovation Fund, C Bio Investors & 8 others	58/100
9th	Omnix Medical 2015, Jerusalem (Israel), Series C	Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections	$25M	Harel Group, Europa & 12 others	57/100
10th	Qpex Biopharma 2018, San Diego (United States), Acquired	Developer of therapies for treating infectious diseases	$33M	New Enterprise Associates, Adams Street Partners ... & 2 others	57/100
173rd	PACE 2023, Cheshire (United Kingdom), Unfunded	Developer of antimicrobial drugs and diagnostics	-	-	24/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on PACE's competitors? Click here to see the top ones

PACE has not made any acquisitions yet. PACE has made 4 investments.

Here is the list of latest three $investments:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Nov 26, 2025	Investments	InnotiveDx	2021	Bath (United Kingdom)
Nov 26, 2024	Investments	Centauri Therapeutics	2014	Kent (United Kingdom)
Nov 20, 2024	Investments	Glox Theraputics	2023	Glasgow (United Kingdom)